$1.04
-0.05-4.59%
最終更新: Nov 6, 7:57 PM
Benzinga
Benzinga
Benzinga
土曜日, 11 07
Benzinga
© 2026 Benzinga | All Rights Reserved
Allogene Therapeutics (ALLO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.15 | $-0.14 | -7.14 % |
| Q2 | Aug 12, 2026 | $-0.13 | $-0.15 | 13.3 % |
| Q1 | May 13, 2026 | $-0.18 | $-0.18 | 0.00 % |
| Q4 | Mar 12, 2026 | $-0.17 | $-0.23 | 26.1 % |
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.14 | $-0.15 | $-0.18 | $-0.23 |
| Actual | $-0.15 | $-0.13 | $-0.18 | $-0.17 |
| Surprise | -7.14% | +13.3% | 0.00% | +26.1% |
| Revenue | ||||
| Estimate | $2220 | $2220 | $1820 | $2000 |
| Actual | $0 | $4.6M | $0 | $0 |
| Surprise | -100.0% | +208909.0% | -100.0% | -100.0% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.14 | $-0.15 | $-0.14 | $-0.13 |
| Revenue | ||||
| Consensus | $2220 | $4000 | — | — |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $0 | $2.22K | -100.0 % |
| Q2 | Aug 12, 2026 | $4.64M | $2.22K | 208909.0 % |
| Q1 | May 13, 2026 | $0 | $1.82K | -100.0 % |
| Q4 | Mar 12, 2026 | $0 | $2.00K | -100.0 % |